surmount-1 trial tirzepatide weight loss non-diabetic SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, Surmount Press Briefing #ADA2022

This episode delves into Retatrutide, a third-generation GLP-1 agonist, explaining its mechanism and how it differs from previous generations like semaglutid...

The general recommendation for a sample size to assess the safety of a weight-reduction drug is 3,000 subjects randomized to the investigational drug within the to-be258 recommended dosage range and no fewer than 1,500 subjects randomized to placebo for at least 1 year of treatment at the maintenance dosage Multiple #obesitytrials have successfully used flexible dosing regimens

Are GLP-1s already changing what youre seeing or are we still underestimating their role relative to other explanations

Ingredients, pricing & verdict.